Klin Farmakol Farm. 2022;36(2):43-47 | DOI: 10.36290/far.2022.008

Lanadelumab in hereditary angioedema treatment

Marta Sobotková
Ústav imunologie 2. LF UK a FN Motol, Praha

Hereditary angioedema is a rare disorder associated with recurrent episodes of swellings in different body areas. C1 inhibitor deficiency is the most common cause of this disease. Bradykinin is considered to be the main mediator responsible for angioedema formation. Fully human monoclonal antibody lanadelumab targets plasma kalikrein, which is responsible for bradykinin formation. It is currently registered for long term prophylaxis in hereditary angioedema and represents a highly effective and well tolerated treatment option in patients with frequent and severe swellings.

Keywords: angioedema, bradykinin, lanadelumab.

Published: July 7, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sobotková M. Lanadelumab in hereditary angioedema treatment. Klin Farmakol Farm. 2022;36(2):43-47. doi: 10.36290/far.2022.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sobotková M, Králíčková P et al. Hereditární angioedém. Praha: Current media s.r.o. 2021.
    2. Maurer M, Magerl M, Ansotegui I et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73(8):1575-1596. Go to original source... Go to PubMed...
    3. Betschel S, Badiou J, Binkley K et al. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol. 2019;15:72. Go to original source... Go to PubMed...
    4. Busse PJ, Christiansen SC, Riedl MA et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150. Go to original source... Go to PubMed...
    5. Krčmová I. (ed.). Hereditární angioedém (HAE) D 84.1 - charakteristika péče v ČR, update 2020. 2020 [cited 2022-05-04]. Available from: https://www.csaki.cz/dokumenty/HAE_dopor_postup.pdf
    6. Souhrn údajů o přípravku Takhzyro. [cited 2022-08-04]. Available from: https://www.ema.europa.eu/en/documents/product-information/takhzyro-epar-product-information_cs.pdf.
    7. Buttgereit T, Vera C, Weller K et al. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. J Allergy Clin Immunol Pract. 2021;9(10):3744-3751. Go to original source... Go to PubMed...
    8. Kenniston JA, Faucette RR, Martik D et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014;289(34):23596-23608. Go to original source... Go to PubMed...
    9. Banerji A, Riedl MA, Bernstein JA et al. HELP Investigators. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018 Nov 27;320(20):2108-2121. Go to original source... Go to PubMed...
    10. Sobotkova M. Lanadelumab. Remedia 2020;30:526-531. Go to original source...
    11. Banerji A, Bernstein JA, Johnston DT et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy. 2022;77(3):979-990. Go to original source... Go to PubMed...
    12. Databáze klinických studií ClinicalTrials.gov. [cited 2022-08-04]. Available from: https://clinicaltrials.gov.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.